Mirum Pharmaceuticals (MIRM) revenue breakdown
By product, Livmarli is the largest at 69% of fiscal 2025 revenue.
Revenue by product
Fiscal years, as Mirum Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $521M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Livmarli | — | — | — | — | $360M | 69% |
| Bile Acid Medicines | — | — | — | — | $161M | 31% |
| Total product sales, net | $3M | $75M | $179M | $336M | — | — |
| License and other revenue | $16M | $2M | $8M | $479,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MIRM.
Open MIRM in InvestinglyQuestions
Where does Mirum Pharmaceuticals make its money?
In fiscal 2025, by product: Livmarli $360M, Bile Acid Medicines $161M.
From Mirum Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.